New drug trial hopes to control recurrent brain tumors

NCT ID NCT06917885

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 23 times

Summary

This early-phase study tests an experimental drug called CUE-102 in 18 adults whose glioblastoma (a type of brain cancer) has returned after initial treatment. The main goal is to check the drug's safety and find the best dose. Participants must have a specific genetic marker (HLA-A*0201). The drug is designed to help the immune system target cancer cells, but it is not expected to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.